A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer

James M. McKiernan, Lamont J. Barlow, Melissa A. Laudano, Mark J. Mann, Daniel P. Petrylak, Mitchell C. Benson

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: Up to 50% of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (Abraxane®, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel. Materials and Methods: Inclusion criteria for this institutional review board approved phase I trial were recurrent high grade Ta, T1 and Tis transitional cell carcinoma of the bladder for which at least 1 prior standard intravesical regimen failed. Six weekly instillations of nanoparticle albumin-bound paclitaxel were administered with a modified Fibonacci dose escalation model used until the maximum deliverable dose was achieved. The primary end point was dose limiting toxicity and the secondary end point was response rate. Results: A total of 18 patients were enrolled in the study. One patient demonstrated measurable systemic absorption after 1 infusion. Grade 1 local toxicities were experienced by 10 (56%) patients with dysuria being the most common, and no grade 2, 3 or 4 drug related local toxicities were encountered. Of the 18 patients 5 (28%) had no evidence of disease at posttreatment evaluation. Conclusions: Intravesical nanoparticle albumin-bound paclitaxel exhibited minimal toxicity and systemic absorption in the first human intravesical phase I trial to our knowledge. A larger phase II study has begun to formally evaluate the activity of this regimen.

Original languageEnglish (US)
Pages (from-to)448-451
Number of pages4
JournalJournal of Urology
Volume186
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Nanoparticles
Bacillus
docetaxel
Therapeutics
Dysuria
Transitional Cell Carcinoma
Research Ethics Committees
Proxy
Solubility
Albumin-Bound Paclitaxel
Urinary Bladder
Recurrence
Pharmaceutical Preparations

Keywords

  • administration
  • intravesical
  • nanotechnology
  • paclitaxel
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. / McKiernan, James M.; Barlow, Lamont J.; Laudano, Melissa A.; Mann, Mark J.; Petrylak, Daniel P.; Benson, Mitchell C.

In: Journal of Urology, Vol. 186, No. 2, 01.08.2011, p. 448-451.

Research output: Contribution to journalArticle

McKiernan, James M. ; Barlow, Lamont J. ; Laudano, Melissa A. ; Mann, Mark J. ; Petrylak, Daniel P. ; Benson, Mitchell C. / A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. In: Journal of Urology. 2011 ; Vol. 186, No. 2. pp. 448-451.
@article{848cb9831f474290b6fa7c7553840218,
title = "A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Gu{\'e}rin refractory nonmuscle invasive bladder cancer",
abstract = "Purpose: Up to 50{\%} of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (Abraxane{\circledR}, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel. Materials and Methods: Inclusion criteria for this institutional review board approved phase I trial were recurrent high grade Ta, T1 and Tis transitional cell carcinoma of the bladder for which at least 1 prior standard intravesical regimen failed. Six weekly instillations of nanoparticle albumin-bound paclitaxel were administered with a modified Fibonacci dose escalation model used until the maximum deliverable dose was achieved. The primary end point was dose limiting toxicity and the secondary end point was response rate. Results: A total of 18 patients were enrolled in the study. One patient demonstrated measurable systemic absorption after 1 infusion. Grade 1 local toxicities were experienced by 10 (56{\%}) patients with dysuria being the most common, and no grade 2, 3 or 4 drug related local toxicities were encountered. Of the 18 patients 5 (28{\%}) had no evidence of disease at posttreatment evaluation. Conclusions: Intravesical nanoparticle albumin-bound paclitaxel exhibited minimal toxicity and systemic absorption in the first human intravesical phase I trial to our knowledge. A larger phase II study has begun to formally evaluate the activity of this regimen.",
keywords = "administration, intravesical, nanotechnology, paclitaxel, urinary bladder neoplasms",
author = "McKiernan, {James M.} and Barlow, {Lamont J.} and Laudano, {Melissa A.} and Mann, {Mark J.} and Petrylak, {Daniel P.} and Benson, {Mitchell C.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.juro.2011.03.129",
language = "English (US)",
volume = "186",
pages = "448--451",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer

AU - McKiernan, James M.

AU - Barlow, Lamont J.

AU - Laudano, Melissa A.

AU - Mann, Mark J.

AU - Petrylak, Daniel P.

AU - Benson, Mitchell C.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Purpose: Up to 50% of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (Abraxane®, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel. Materials and Methods: Inclusion criteria for this institutional review board approved phase I trial were recurrent high grade Ta, T1 and Tis transitional cell carcinoma of the bladder for which at least 1 prior standard intravesical regimen failed. Six weekly instillations of nanoparticle albumin-bound paclitaxel were administered with a modified Fibonacci dose escalation model used until the maximum deliverable dose was achieved. The primary end point was dose limiting toxicity and the secondary end point was response rate. Results: A total of 18 patients were enrolled in the study. One patient demonstrated measurable systemic absorption after 1 infusion. Grade 1 local toxicities were experienced by 10 (56%) patients with dysuria being the most common, and no grade 2, 3 or 4 drug related local toxicities were encountered. Of the 18 patients 5 (28%) had no evidence of disease at posttreatment evaluation. Conclusions: Intravesical nanoparticle albumin-bound paclitaxel exhibited minimal toxicity and systemic absorption in the first human intravesical phase I trial to our knowledge. A larger phase II study has begun to formally evaluate the activity of this regimen.

AB - Purpose: Up to 50% of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (Abraxane®, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel. Materials and Methods: Inclusion criteria for this institutional review board approved phase I trial were recurrent high grade Ta, T1 and Tis transitional cell carcinoma of the bladder for which at least 1 prior standard intravesical regimen failed. Six weekly instillations of nanoparticle albumin-bound paclitaxel were administered with a modified Fibonacci dose escalation model used until the maximum deliverable dose was achieved. The primary end point was dose limiting toxicity and the secondary end point was response rate. Results: A total of 18 patients were enrolled in the study. One patient demonstrated measurable systemic absorption after 1 infusion. Grade 1 local toxicities were experienced by 10 (56%) patients with dysuria being the most common, and no grade 2, 3 or 4 drug related local toxicities were encountered. Of the 18 patients 5 (28%) had no evidence of disease at posttreatment evaluation. Conclusions: Intravesical nanoparticle albumin-bound paclitaxel exhibited minimal toxicity and systemic absorption in the first human intravesical phase I trial to our knowledge. A larger phase II study has begun to formally evaluate the activity of this regimen.

KW - administration

KW - intravesical

KW - nanotechnology

KW - paclitaxel

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=79960194055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960194055&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.03.129

DO - 10.1016/j.juro.2011.03.129

M3 - Article

C2 - 21680003

AN - SCOPUS:79960194055

VL - 186

SP - 448

EP - 451

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -